Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

751 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer.
Hecht M, Eckstein M, Rutzner S, von der Grün J, Illmer T, Klautke G, Laban S, Hautmann MG, Brunner TB, Tamaskovics B, Hinke A, Zhou JG, Frey B, Donaubauer AJ, Becker I, Semrau S, Hartmann A, Balermpas P, Budach W, Gaipl US, Iro H, Gostian AO, Fietkau R. Hecht M, et al. Among authors: eckstein m. J Immunother Cancer. 2022 Jan;10(1):e003747. doi: 10.1136/jitc-2021-003747. J Immunother Cancer. 2022. PMID: 35078923 Free PMC article. Clinical Trial.
Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naïve stage T1 high-grade urothelial bladder cancer.
Otto W, van Rhijn BW, Breyer J, Bertz S, Eckstein M, Mayr R, Lausenmeyer EM, Denzinger S, Burger M, Hartmann A. Otto W, et al. Among authors: eckstein m. Int J Urol. 2018 May;25(5):442-449. doi: 10.1111/iju.13532. Epub 2018 Feb 22. Int J Urol. 2018. PMID: 29473226
The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes.
Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM, Wullweber A, Taubert H, Breyer J, Otto W, Worst T, Burger M, Wullich B, Bolenz C, Fuhrich N, Geppert CI, Weyerer V, Stoehr R, Bertz S, Keck B, Erlmeier F, Erben P, Hartmann A, Strick R, Eckstein M; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany. Pfannstiel C, et al. Among authors: eckstein m. Cancer Immunol Res. 2019 Jun;7(6):923-938. doi: 10.1158/2326-6066.CIR-18-0758. Epub 2019 Apr 15. Cancer Immunol Res. 2019. PMID: 30988029
PD-L1 assessment in urothelial carcinoma: a practical approach.
Eckstein M, Cimadamore A, Hartmann A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Gevaert T. Eckstein M, et al. Ann Transl Med. 2019 Nov;7(22):690. doi: 10.21037/atm.2019.10.24. Ann Transl Med. 2019. PMID: 31930091 Free PMC article. Review.
Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell Carcinoma.
Sommer U, Eckstein M, Ammann J, Braunschweig T, Macher-Göppinger S, Schwamborn K, Hieke-Schulz S, Harlow G, Flores M, Wullich B, Wirth M, Roth W, Knüchel R, Weichert W, Baretton G, Hartmann A. Sommer U, et al. Among authors: eckstein m. Clin Genitourin Cancer. 2020 Oct;18(5):e629-e642. doi: 10.1016/j.clgc.2020.02.009. Epub 2020 Feb 15. Clin Genitourin Cancer. 2020. PMID: 32178978 Free article.
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.
Morsch R, Rose M, Maurer A, Cassataro MA, Braunschweig T, Knüchel R, Vögeli TA, Ecke T, Eckstein M, Weyerer V, Esposito I, Ackermann M, Niegisch G, Gaisa NT; German Study Group of Bladder Cancer (DFBK e.V.). Morsch R, et al. Among authors: eckstein m. BMC Cancer. 2020 Mar 18;20(1):230. doi: 10.1186/s12885-020-06727-2. BMC Cancer. 2020. PMID: 32188412 Free PMC article.
751 results